ACRES Commercial Realty Corp. (NYSE:ACR) Q3 2024 Earnings Conference Call October 31, 2024 10:00 AM ET Company Participants Kyle Brengel - VP of Operations Mark Fogel - President and CEO Eldron Blackwell - CFO Andrew Fentress - Chairman Conference Call Participants Matthew Erdner - Jones Trading Stephen Laws - Raymond James Chris Muller - Citizens JPM Operator Good day, ladies and gentlemen, and welcome to the Third Quarter 2024 ACRES Commercial Realty Corp. Earnings Conference Call. Currently, all particip ...

| --- | --- | --- | --- | --- | --- | |-------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | THIRD QUARTER 2024 EARNINGS PRESENTATION | | | | | | | October 30, 2024 | | | | | | | | | | | | | DISCLAIMER ACRESREIT.COM 2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of federal securities laws. These forward-looking statements are not historical facts but rather are based on ACRES Commercial Realty ...

ACRES Commercial (ACR) came out with quarterly earnings of $0.24 per share, missing the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -38.46%. A quarter ago, it was expected that this commercial real estate investment trust would post earnings of $0.35 per share when it actually produced earnings of $0.51, delivering a surprise of 45.71%.Over the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share ACR New York Stock Exchange 8.625% Fixed-to-Floating Series C Cumulative Redeemable Preferred Stock ACRPrC New York Stock Exchange 7.875% Series D Cumulative Redeemable Preferred Stock ACRPrD New York Stock Exchange FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of ...

CARMIEL, Israel, Oct. 25, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that data from the phase I clinical trial of PRX-115, the Company's recombinant PEGylated uricase product candidate in development for the treatment of uncontrolled gout, will be presented ...

SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that preclinical data will be presented from NX-5948, Nurix’s proprietary BTK degrader currently in Phase 1b development for B-cell malignancies and in IND enabling studies for autoimmune disease, and GS-6791/NX-0479, an IRAK4 degrader discovered in co ...

– Through selective inhibition of proinflammatory transcription, p300 KAT inhibition modulates the activity and function of multiple pro-inflammatory signaling pathways that drive chronic inflammatory diseases – – Oral presentation taking place on Monday, November 18, 2024, from 4:15 p.m. to 4:30 p.m. EST – SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other di ...

ACRES Commercial Realty (NYSE: ACR ) last paid a quarterly cash dividend in January 2020. This was a few months before the pandemic would spark global stay-at-home orders and roughly two years before mortgage REITs would faceThe equity market is a powerful mechanism as daily fluctuations in price get aggregated to incredible wealth creation or destruction over the long term. Pacifica Yield aims to pursue long-term wealth creation with a focus on undervalued yet high-growth companies, high-dividend tickers, ...

Acrivon Therapeutics, Inc. (NASDAQ: ACRV ), a relatively under-the-radar player in the biotech universe, has been quietly making waves in the precision oncology space. Leveraging its proprietary proteomics platform, ACRV is developing targeted therapies that could revolutionizeAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my ...

Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer Achieved statistically significant segregation of responders in BM+ vs BM- subgroups based on OncoSignature patient selection (p-value = 0.009) ACR-368 endometrial cohort data maturing with all responders still on therapy; mDoR not yet reached (~6 months at time of data-cut) Endometrial cancer now anticipated to be the first tumor type wit ...